ClinicalTrials.gg
DrugBiological

flt3 ligand protein clinical trials

Also written CDX-301.

Includes 9 studies of CDX-301.

studies test it
17
open now
2
in phase 3
1
first study started
1998

How each study uses flt3 ligand protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the flt3 ligand protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

recombinant flt3 ligand
5
FLT3 Ligand
3
FLT 3 Ligand
2
Flt3-Ligand
2
Flt3L
2

Development codes

CDX-301
2

Studies by the year they started

17 studies that test it; most in 2014 (4)

Studies that test flt3 ligand protein, by start year
YearStudies
19982
20001
20011
20111
20144
20161
20192
20201
20211
20222
20231

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
9
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 14

National Cancer Institute (NCI) (3) · Celldex Therapeutics (3) · University of Southern California (1) · Dana-Farber Cancer Institute (1) · Icahn School of Medicine at Mount Sinai (1) · Montefiore Medical Center (1) · Parker Institute for Cancer Immunotherapy (1) · Joshua Brody (1)

Often tested with

Tested in the same studies.

Poly ICLC (5) · CDX-1140 (3) · NeoVax (1) · Fms-Related Tyrosine Kinase 3 Ligand (1) · Bempegaldesleukin (1) · DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151 (1) · Pembrolizumab (1) · Glembatumumab vedotin (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test flt3 ligand protein.

Studies

Open first, then newest update. How each study uses flt3 ligand protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 3 — flt3 ligand protein is usual care or a partner of the new treatment

Codes

What other systems call flt3 ligand protein · ClinicalTrials.gg INT003766

  • MeSH (NLM) C084881flt3 ligand proteinOne source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.